DCPrime BV   Report issue

For profit Phase 1 Phase 2
Founded: Leiden Netherlands (2006)

Organization Overview

First Clinical Trial
2011
NCT01373515
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DCPrime BV

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: DCPrime BV (1) Acquired (4)

dcp-001 (2 trials)

ilixadencel (3 trials)

pembrolizumab (keytruda) (1 trial)

sunitinib (sutent) (1 trial)

tumor-pulsed dendritic cells (2 trials)

Drugs in Phase 1 Trials (1)

Key: DCPrime BV (0) Acquired (1)

allogeneic dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 6